General Information and Variability Data of DT
DT ID DTD0008
Gene Name SLCO1B1
Protein Name Organic anion transporting polypeptide 1B1
Synonyms LST-1; LST1; Liver-specific organic anion transporter 1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Solute carrier organic anion transporter family member 1B1
Gene ID
10599
UniProt ID
Q9Y6L6
TCDB ID
2.A.60.1.5
DT Family Organo Anion Transporter (OAT) Family ;
Tissue Specificity High expressed in sinusoidal (basolateral) membrane of hepatocytes, and is expressed uniformly throughout the lobules
Function This transporter involved in the clearance of bile acids and organic anions from the liver. Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine.
Disease(s) Breast cancer [ICD-11: 2C60-2C6Z]
Chronic hepatitis C infection [ICD-11: 1E51.1]
Diabetes [ICD-11: 5A10-5A14]
Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01]
Dyslipidaemias [ICD-11: 5C8Z]
Edema associated with congestive heart failure [ICD-11: BD10]
Leukemia [ICD-11: 2A60-2B33]
Metastatic colorectal cancer [ICD-11: 2B91]
Pemphigus vulgaris [ICD-11: EB40.0]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Atorvastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [1]
Axitinib Drug Info Advanced renal cell carcinoma [ICD-11: 2C90] Approved [2]
Bosentan Drug Info Pulmonary arterial hypertension [ICD-11: BB01.0] Approved [3]
Bromfenac Drug Info Ocular inflammation [ICD-11: 9C61.24] Approved [4]
Caspofungin Drug Info Fungal infections [ICD-11: 1F20-1F2Z] Approved [5]
Cefazolin Drug Info Methicillin-susceptible staphylococcus aureus [ICD-11: 1B74.0] Approved [5]
Cefditoren Drug Info Acute bacterial exacerbation of chronic bronchitis [ICD-11: CA20.1] Approved [5]
Cefoperazone Drug Info Pseudomonas bacterial infections [ICD-11: 1B92] Approved [5]
Cerivastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [6]
Chenodeoxycholic acid Drug Info Primary biliary cirrhosis [ICD-11: DB96.1] Approved [7]
Cholic acid Drug Info Synthesis disorders [ICD-11: 5C52.10] Approved [5]
Cilostazol Drug Info Intermittent claudication [ICD-11: BD40.00] Approved [8]
Crizotinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [9]
Darunavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [5]
Dasatinib Drug Info Multiple myeloma [ICD-11: 2A83] Approved [9]
Dehydroepiandrosterone sulfate Drug Info Dyspareunia [ICD-11: GA12] Approved [5]
Dinoprostone Drug Info Medical abortion [ICD-11: JA00.1] Approved [5]
Docetaxel Drug Info Lung cancer [ICD-11: 2C25] Approved [6]
Eluxadoline Drug Info Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Approved [10]
Enalapril Drug Info High blood pressure [ICD-11: BA00] Approved [11]
Entacapone Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [4]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [12]
Etoposide Drug Info Testicular cancer [ICD-11: 2C80] Approved [13]
Ezetimibe Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [14]
Fluorescein Drug Info Ocular disease [ICD-11: 9E1Z] Approved [4]
Fluvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [15]
Gadobenate dimeglumine Drug Info CNS imaging [ICD-11: XD47Y1] Approved [16]
Gefitinib Drug Info Urethral cancer [ICD-11: 2F78] Approved [9]
Hydroxyurea Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [17]
Imatinib Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [9]
Levothyroxine Drug Info Hypothyroidism [ICD-11: 5A00.2] Approved [18]
Liothyronine Drug Info Hypothyroidism [ICD-11: 5A00.2] Approved [18]
Lopinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [5]
Lovastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [19]
Mesalazine Drug Info Recurrent ventricular fibrillation [ICD-11: BC71.1] Approved [20]
Methotrexate Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [21]
Mycophenolate mofetil Drug Info Pemphigus vulgaris [ICD-11: EB40.0] Approved [22]
Nafcillin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [5]
Nateglinide Drug Info Diabetes [ICD-11: 5A10-5A14] Approved [4]
Nilotinib Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [9]
Olmesartan medoxomil Drug Info High blood pressure [ICD-11: BA00] Approved [23]
Ouabain Drug Info Heart failure [ICD-11: BD1Z] Approved [24]
Paclitaxel Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [25]
Pazopanib hydrochloride Drug Info Renal cell carcinoma [ICD-11: 2C90] Approved [5]
Pitavastatin Drug Info Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z] Approved [26]
Pitavastatin calcium Drug Info Dyslipidaemias [ICD-11: 5C8Z] Approved [27]
Pravastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [27]
Regorafenib Drug Info Metastatic colorectal cancer [ICD-11: 2B91] Approved [28]
Repaglinide Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [29]
Rifampicin Drug Info Tuberculosis [ICD-11: 1B1Z] Approved [30]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [31]
Saquinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [5]
Simeprevir Drug Info Chronic hepatitis C infection [ICD-11: 1E51.1] Approved [32]
Simvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [33]
Sirolimus Drug Info Organ transplant rejection [ICD-11: NE84] Approved [34]
Sorafenib Drug Info Pancreatic cancer [ICD-11: 2C10] Approved [9]
Sunitinib Drug Info Imatinib-resistant gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [9]
Technetium (99MTC) mebrofenin Drug Info Imaging of liver and gallbladder [ICD-11: XD47Y1] Approved [29]
Temocapril Drug Info High blood pressure [ICD-11: BA00] Approved [5]
Torsemide Drug Info Edema associated with congestive heart failure [ICD-11: BD10] Approved [35]
Valsartan Drug Info High blood pressure [ICD-11: BA00] Approved [24]
Vandetanib Drug Info Thyroid gland tumours [ICD-11: 2D10] Approved [9]
Vemurafenib Drug Info Thyroid cancer [ICD-11: 2D10] Approved [9]
Clinical Trial Drug(s) Transported by This DT Benzylpenicillin Drug Info Gram-positive bacteria infections [ICD-11: 1A00-1H0Z] Phase 4 [5]
Primovist Drug Info Lung cancer [ICD-11: 2C25] Phase 4 [5]
Atrasentan Drug Info Endothelial dysfunction [ICD-11: BE2Z] Phase 3 [5]
Glycocholic acid Drug Info Bile acid synthesis defect [ICD-11: 5C52.11] Phase 3 [5]
Karenitecin Drug Info Ovarian cancer [ICD-11: 2C73] Phase 3 [5]
BQ-123 Drug Info ST-Elevation myocardial infarction [ICD-11: BA41.0] Phase 2 [5]
Cholyl lysyl fluorescein Drug Info Hepatitis virus infection [ICD-11: 1E5Z] Phase 2 [5]
Danoprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 2 [6]
Flavopiridol Drug Info Chronic lymphocytic leukemia [ICD-11: 2A82.0] Phase 2 [5]
SN-38 Drug Info Colon cancer [ICD-11: 2B90.Z] Phase 2 [5]
YM758 Drug Info Angina pectoris [ICD-11: BA40] Phase 2 [5]
Gimatecan Drug Info Brain and central nervous system tumors [ICD-11: 2A00] Phase 1/2 [5]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT TR-14035 Drug Info Multiple scierosis [ICD-11: 8A40] Discontinued in Phase 1 [36]
Leukotriene E4 Drug Info Asthma [ICD-11: CA23] Preclinical [5]
Sodium taurocholate Drug Info Type 2 diabetes [ICD-11: 5A11] Preclinical [24]
[D-Ala2, D-Leu5]-enkephalin Drug Info Pain [ICD-11: MG30-MG7Z] Preclinical [5]
Sincalide Drug Info Discovery agent [ICD-11: N.A.] Preclinical [5]
Taurocholic acid Drug Info Type 2 diabetes [ICD-11: 5A11] Terminated [18]
Endogenous Substrate(s) Bisglucuronosyl bilirubin; Cholate; Dehydroepiandrosterone sulfate; Eicosanoids; Monoglucuronosyl bilirubin; Thyroid hormones; Tauroursodeoxycholate
Endogenous Metabolites (EMs) Handled by This DT Bile salt unspecific EM Info Unclear experiment used for identifying this EM [37]
Hormone metabolite unspecific EM Info Unclear experiment used for identifying this EM [37]
Thyroxine EM Info Unclear experiment used for identifying this EM [37]
Triiodothyronine EM Info Unclear experiment used for identifying this EM [37]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Atorvastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.77 microM [38]
Atorvastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 12.4 microM [39]
Atorvastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 18.9 microM [40]
Bilirubin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.1 microM [41]
Bilirubin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.28 microM [41]
Bilirubin Drug Info Oocytes-OATP1B1 Km = 0.0076 microM [42]
Bosentan Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 44 microM [3]
Bromsulphthalein Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.14 microM [41]
Bromsulphthalein Drug Info Oocytes-OATP1B1 Km = 0.3 microM [43]
Cilostazol Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 17.7 microM [8]
Estradiol-17beta-glucuronide Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 5.4 microM [44]
Estradiol-17beta-glucuronide Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 5.9 microM [45]
Estradiol-17beta-glucuronide Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 2.5 microM [46]
Estradiol-17beta-glucuronide Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 8.29 microM [47]
Estrone sulfate Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 0.23 microM [48]
Estrone sulfate Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 2.4 microM [44]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 12.5 microM [41]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.46 microM [47]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.0675 microM [49]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 7 microM [49]
Estrone sulfate Drug Info Oocytes-OATP1B1 Km = 0.094 microM [49]
Estrone sulfate Drug Info Oocytes-OATP1B1 Km = 5.34 microM [49]
Fluo-3 Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 2.3 microM [44]
Fluvastatin Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 1.4 microM [48]
Fluvastatin Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 3.5 microM [48]
Fluvastatin Drug Info Oocytes-OATP1B1 Km = 31.1 microM [27]
Levothyroxine Drug Info Oocytes-OATP1B1 Km = 3 microM [18]
Liothyronine Drug Info Oocytes-OATP1B1 Km = 2.7 microM [18]
Mesalazine Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 55.1 microM [20]
Olmesartan medoxomil Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 12.8 microM [50]
Olmesartan medoxomil Drug Info Oocytes-OATP1B1 Km = 42.6 microM [23]
Pitavastatin calcium Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 3 microM [47]
Pitavastatin calcium Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 4.8 microM [51]
Pitavastatin calcium Drug Info Oocytes-OATP1B1 Km = 3.6 microM [52]
Pitavastatin calcium Drug Info Oocytes-OATP1B1 Km = 6.7 microM [27]
Pravastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 33.7 microM [19]
Pravastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 85.7 microM [39]
Pravastatin Drug Info Oocytes-OATP1B1 Km = 57.5 microM [27]
Rifampicin Drug Info Human cervical cancer cell line (Hela)-OATP1B1 Km = 1.5 microM [30]
Rifampicin Drug Info Oocytes-OATP1B1 Km = 13 microM [53]
Rosuvastatin Drug Info Human cervical cancer cell line (Hela)-OATP1B1 Km = 4 microM [54]
Rosuvastatin Drug Info Human cervical cancer cell line (Hela)-OATP1B1 Km = 7.3 microM [54]
Rosuvastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.8 microM [31]
Rosuvastatin Drug Info Oocytes-OATP1B1 Km = 8.5 microM [55]
Taurocholic acid Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 33.8 microM [19]
Taurocholic acid Drug Info Oocytes-OATP1B1 Km = 13.6 microM [18]
Valsartan Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 17.8 microM [56]
Valsartan Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 1.39 microM [57]
References
1 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
2 Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
3 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
4 Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
5 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
6 FDA Drug Development and Drug Interactions
7 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
8 Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
9 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
10 Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42.
11 The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6.
12 Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci. 2009 Nov;18(11):2298-306.
13 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
14 A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50.
15 SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
16 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
17 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
18 Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
19 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
20 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
21 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
22 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
23 OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
24 Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
25 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
26 Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012 Aug 30;47(1):244-55.
27 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
28 Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
29 Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
30 Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8.
31 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
32 Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
33 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
34 Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
35 Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
36 Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):209-21.
37 Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1). Biochim Biophys Acta. 2016 Nov;1858(11):2894-2902.
38 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
39 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
40 effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):194-204.
41 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30.
42 Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J. 2003 May 1;371(Pt 3):897-905.
43 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
44 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
45 Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. Pharmacol Res. 2009 Jul;60(1):50-6.
46 Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005 Jul;35(7):737-53.
47 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
48 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
49 Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9.
50 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
51 The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos. 2012 Aug;40(8):1641-8.
52 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
53 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
54 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
55 Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004 Aug;76(2):167-77.
56 Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611.
57 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.